155 related articles for article (PubMed ID: 37980163)
21. A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation.
Wang S; Alpsoy A; Sood S; Ordonez-Rubiano SC; Dhiman A; Sun Y; Jiao G; Krusemark CJ; Dykhuizen EC
Chembiochem; 2021 Jul; 22(13):2335-2344. PubMed ID: 33950564
[TBL] [Abstract][Full Text] [Related]
22. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma.
Tang B; Tian Y; Liao Y; Li Z; Yu S; Su H; Zhong F; Yuan G; Wang Y; Yu H; Tomlinson S; Qiu X; He S
Cell Death Dis; 2019 Jan; 10(2):52. PubMed ID: 30718464
[TBL] [Abstract][Full Text] [Related]
23. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
Xia H; Ooi LL; Hui KM
PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
[TBL] [Abstract][Full Text] [Related]
24. Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer.
Iqbal MA; Siddiqui S; Ur Rehman A; Siddiqui FA; Singh P; Kumar B; Saluja D
Mol Oncol; 2021 May; 15(5):1450-1465. PubMed ID: 33400401
[TBL] [Abstract][Full Text] [Related]
25. Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer.
Xie X; Liang H; Jiangting W; Wang Y; Ma X; Tan Z; Cheng L; Luo Z; Wang T
Front Mol Biosci; 2023; 10():1198557. PubMed ID: 37484531
[No Abstract] [Full Text] [Related]
26. LncAY controls BMI1 expression and activates BMI1/Wnt/β-catenin signaling axis in hepatocellular carcinoma.
Chen MH; Fu LS; Zhang F; Yang Y; Wu XZ
Life Sci; 2021 Sep; 280():119748. PubMed ID: 34174322
[TBL] [Abstract][Full Text] [Related]
27. CBX2 depletion inhibits the proliferation, invasion and migration of gastric cancer cells by inactivating the YAP/β-catenin pathway.
Zeng M; Li B; Yang L; Guan Q
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313949
[TBL] [Abstract][Full Text] [Related]
28. Single Nucleotide Polymorphisms of
Tan C; Bei C; Zhu X; Zhang Y; Qin L; Tan S
Biomed Res Int; 2019; 2019():6436825. PubMed ID: 31211140
[TBL] [Abstract][Full Text] [Related]
29. Identification of Biomarkers Associated with Hepatocellular Carcinoma Stem Cell Characteristics Based on Co-Expression Network Analysis of Transcriptome Data and Stemness Index.
Zhao Z; Mu H; Feng S; Liu Y; Zou J; Zhu Y
Crit Rev Eukaryot Gene Expr; 2022; 32(2):47-60. PubMed ID: 35381131
[TBL] [Abstract][Full Text] [Related]
30. FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness.
Loh JJ; Li TW; Zhou L; Wong TL; Liu X; Ma VWS; Lo CM; Man K; Lee TK; Ning W; Tong M; Ma S
Cancer Res; 2021 Nov; 81(22):5692-5705. PubMed ID: 34551961
[TBL] [Abstract][Full Text] [Related]
31. Identification of potentially functional circular RNAs hsa_circ_0070934 and hsa_circ_0004315 as prognostic factors of hepatocellular carcinoma by integrated bioinformatics analysis.
Morovat P; Morovat S; Ashrafi AM; Teimourian S
Sci Rep; 2022 Mar; 12(1):4933. PubMed ID: 35322101
[TBL] [Abstract][Full Text] [Related]
32. CASC9 Facilitates Cell Proliferation in Bladder Cancer by Regulating CBX2 Expression.
Huo W; Tan D; Chen Q
Nephron; 2020; 144(8):388-399. PubMed ID: 32570259
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis.
Qiao Y; Yuan F; Wang X; Hu J; Mao Y; Zhao Z
Cancer Biomark; 2022; 35(2):227-243. PubMed ID: 36120772
[TBL] [Abstract][Full Text] [Related]
34. MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55.
Yin Y; Cai J; Meng F; Sui C; Jiang Y
Cancer Biol Ther; 2018 Apr; 19(4):306-315. PubMed ID: 29561704
[TBL] [Abstract][Full Text] [Related]
35. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
36. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma.
Wu ZH; Yang DL; Wang L; Liu J
Front Immunol; 2021; 12():793343. PubMed ID: 34925377
[TBL] [Abstract][Full Text] [Related]
38. MiR-30a-5p inhibits cell behaviors in esophageal cancer via modulating CBX2.
Peng L; Huang X; Qing D; Lu H; Liu X; Chen J; Long X; Pang Q
Mutat Res; 2023; 826():111818. PubMed ID: 37196609
[TBL] [Abstract][Full Text] [Related]
39. Construction and Comprehensive Analyses of a Competing Endogenous RNA Network in Tumor-Node-Metastasis Stage I Hepatocellular Carcinoma.
Gu X; Li H; Sha L; Zhao W
Biomed Res Int; 2020; 2020():5831064. PubMed ID: 32104698
[TBL] [Abstract][Full Text] [Related]
40. CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma.
Shao S; Cao H; Wang Z; Zhou D; Wu C; Wang S; Xia D; Zhang D
Clin Epigenetics; 2020 Feb; 12(1):31. PubMed ID: 32070428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
